SEC 13F Intelligence

Venrock Adviser, LLC / SYRE

Venrock Adviser, LLC’s Spyre Therapeutics Inc Position

Does Venrock Adviser, LLC own Spyre Therapeutics Inc (SYRE)? Yes — 3.69M shares worth $186M (+6.94% of its 13F portfolio) as of Q1 2026.

Position Value
$186M
Q1 2026
Shares
3.69M
% of Portfolio
+6.94%
Quarters Held
10
currently held

Position History SYRE

Reported value by quarter
Q4 ’23: $51MQ4 ’23Q1 ’24: $82MQ2 ’24: $63MQ2 ’24Q3 ’24: $79MQ4 ’24: $63MQ4 ’24Q1 ’25: $43MQ2 ’25: $40MQ2 ’25Q3 ’25: $45MQ4 ’25: $121MQ4 ’25Q1 ’26: $186Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20263.69M$186M+6.94%
Q4 20253.69M$121M+5.96%
Q3 20252.69M$45M+2.53%
Q2 20252.69M$40M+3.01%
Q1 20252.69M$43M+3.69%
Q4 20242.69M$63M+4.29%
Q3 20242.69M$79M+4.14%
Q2 20242.69M$63M+4.02%
Q1 20242.17M$82M+3.92%
Q4 20232.37M$51M+3.50%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Venrock Adviser, LLC’s full portfolio or all institutional holders of SYRE.